Experiences with

Nivolumab

Am getting my first treatment of cabizataxel/carboplatin/nivolumab/ipilimumab this coming Tuesday as part of the Duke CHAMP trial: https://www.dukehealth.org/clinical-trials/directory/pro00106278 Does anyone have recommendations/experiences on how to best reduce side effects?

Drug/Therapy (Mechanism / Status) Sipuleucel-T (Autologous dendritic cell vaccine; approved) Pembrolizumab (PD-1 checkpoint inhibitor; approved for MSI-high) Ipilimumab (CTLA-4 checkpoint inhibitor; experimental in PC) Nivolumab + Ipilimumab (PD-1 + CTLA-4 combo; experimental) Thalidomide (Immunomodulator

Patients received nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) every three weeks for four cycles, followed by maintenance nivolumab therapy. The primary endpoint was the disease control rate exceeding six months.

The U.S. FDA has approved nivolumqb plus ipilimumab for dMMR / MSI-H metastatic colorectal cancer. GCCA President, Nicole Sheahan, commented, “Colorectal cancer is the third most commonly diagnosed cancer and the second most common cause of cancer-related death for men and women combined in the U.S.,

Nivolumab was given intravenously on the first day of each 28-day cycle.

I've been on immunotherapy with ipilumumab and nivolumab with no new disease since 10/2022; my oncologist is beyond enthusiastic about my response to immunotherapy and I'm pretty happy, too.

Now have metastases to ureter ( not v usual) and am about to start more Folfox with Nivolumab for three months. Seems the prognosis depends on how well I respond to this treatment. Anyone with similar experience able to pass on any thoughts etc?? Thank you

BAT + nivolumab has been trialed. https://clinicaltrials.gov/ct2/show/NCT03554317 Nivo is an immunomodulator/immune checkpoint inhibitor/PD-L1 inhibitor.

of nivolumab co-formulated with rHuPH20, compared with IV nivolumab in patients with advanced or metastatic ccRCC who have previously received systemic therapy.1 A total of 495 patients were randomly assigned to receive either subcutaneous nivolumab or IV nivolumab.

Mark Linch presented results from the NEPTUNES (NCT03061539), a multi-centre two-cohort, biomarker-selected phase 2 trial evaluating Nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) for metastatic prostate cancer with an immunogenic signature. Dr.

Nivolumab (Opdivo): Nivolumab is another checkpoint inhibitor that targets PD-1. Like pembrolizumab, nivolumab has been studied in clinical trials for advanced prostate cancer, often in combination with other therapies.

It would be the solo drug for me, not the other arms of the trial which includes avastin and nivolumab in conjunction with trial drug. Thanks

The trial combines checkpoint inhibitors (nivolumab and ipilimumab) with SVV-001, an oncolytic virus that targets and bursts tumor cells, sparking an immune response. The virus turns “cold” tumors “hot,” making them responsive to immunotherapy, which then amplifies the attack.

An encouraging Opdivo/Yervoy study was presented at ASCO recently, which gave me a little more hope for the future. https://www.onclive.com/view/nivolumab-ipilimumab-bests-nivolumab-in-ovarian-and-extra-renal-clear-cell-carcinomas Yervoy (ipilimumab) is an anti-CTLA-4, which apparently has higher risk

-Patrick [1] https://pubmed.ncbi.nlm.nih.gov/38167882/ [2] https://en.wikipedia.org/wiki/Nivolumab

Depending on the results do we get access to some novel drugs like olapariv or nivolumab, etc, that might help us ? 🫠thanks, Manilo.

not yet tested for prostate cancer (I think) but still… “But two years after starting a treatment regimen that combined ruxolitinib with the checkpoint inhibitor nivolumab—a current standard of care—87% of patients were still alive, and 46% stopped exhibiting signs of cancer progression altogether.”

I also found an ongoing trial immunotherapy trial IMPACT (NCT03570619) which combines other drugs used for immunotherapy with CDK12 (ie: Nivolumab and Ipilimumab) Has anyone here in the community had success on either of these trials?

"No patients met the primary endpoint of complete PSA response; however, 4/19 (21%) patients had a PSA decline >50%. Median PSA doubling times were 5.9 months pretreatment, 25.6 months on-treatment (p=0.001), and 9.0 months in the subsequent year off-treatment. The overall median radiographic progression-free

NIVOLUMAB will shortly be assessed by the Scottish Medicine Consortium (SMC) for use in NHS Scotland in combination with platinum-based chemotherapy for the neoadjuvant treatment (this is treatment given before surgery) for resectable non-small cell lung cancer in adults.